johnson and johnson

What Buffett's Buying: A Stake in Fiserv, More J&J

Each quarter, investors and the media await the latest filing from Warren Buffett's Bekshire Hathaway to see what changes the Oracle of Omaha made to his portfolio. But why is he buying a piece of payment processor Fiserv and raising his stake in Johnson & Johnson?

Johnson & Johnson Earnings Up, but Recalls Cut Guidance

Johnson & Johnson's earnings for the second quarter of 2010 rose 5.4% to $3.4 billion, or $1.23 per share, from $3.2 billion or $1.15 per share, the company announced Tuesday morning. Adjusted earnings, which exclude litigation costs, were $1.21 per share.

McNeil Expands Recall of Tylenol, Motrin, Benadryl

Johnson & Johnson subsidiary McNeil recalled another batch of over-the-counter medicines Thursday. The specific lots of Tylenol, Motrin and Benadryl products may have been contaminated with trace amounts of a chemical that gives them a musty or moldy odor.

Legal Briefing: DOJ May Sue to Block Ariz. Immigration Law

The Department of Justice may file suit Tuesday over Arizona's controversial immigration law, but if the lawsuit is crafted as has been rumored, it will frustrate all sides in the debate, because it avoids the merits of the law and focuses instead on Arizona's lack of authority to enact it.

Why J&J's Recall of Children's Tylenol Matters

So far the stock market has yawned at the latest Johnson & Johnson consumer products recall, which follows several recalls last fall and in January. Sales of Tylenol are drops in the bucket for the company, but what happens if the public sours on the trusted J&J brand?

Buffett Tweaks $58 Billion Portfolio

Billionaire Warren Buffett's company has reduced its holdings in Johnson & Johnson (JNJ), Proctor & Gamble (PG), ConocoPhillips (COP) and Exxon Mobil (XOM) during the last three months of 2009. Berkshire Hathaway (BRK.A) disclosed those investments and several other changes to its roughly $58 billion U.S. stock portfolio in documents filed with the Securities and Exchange Commission on Tuesday. The filing offers a snapshot of the Omaha-based company's holdings as of Dec. 31.

Will Casey Johnson's Estate Enjoy a Tax Loophole?

Casey Johnson, found dead Jan. 4 at age 30, and Ruth Lilly, who died Dec. 31 at age 94, were both heirs to huge family fortunes -- and both died right around the moment when a U.S. tax loophole took effect, with the potential to cost billions in revenue and to drive estate-planning lawyers crazy.

GlaxoSmithKline's Witty: Do-Gooder or Good at PR?

He's young, charismatic, innovative and has got heart. At least that's the impression GlaxoSmithKline CEO Andrew Witty gives to the outside world. GSK is allowing free access to its library of 13,500 potential malaria treatments. Is he genuinely a do-gooder or just good at PR?

Casey Johnson, Dead at 30, Enjoyed Family Wealth but Chose Fame

For Johnson & Johnson (JNJ) heiress Casey Johnson, 30, the battle between a desire for media attention and her family's struggle for privacy translated into a painful choice between wealth and fame. On Monday, the struggle ended sadly: Johnson found dead of undetermined causes in her Los Angeles home.

Sanofi-Aventis Buys Chattem, a Leader in Over-the-Counter Sales

Sanofi-Aventis announced Monday it will acquire Chattem Inc. for about $1.9 billion -- paying $93.50 per share, a 34% premium over Chattem's closing price Friday. The deal will create the world's fifth-largest consumer health-care company by revenues and helps Sanofi diversify into over-the-counter and consumer brands: a strategy used by Johnson & Johnson, and one many pharmas seek to adopt before the coming patent cliff.

Ten Stocks for 2010

By many measures, this past decade was a downer. We experienced the dot-com bust, terrorism attacks, the Enron scandal, Bernie Madoff's Ponzi scheme,...